Cardiovasculaire Geneeskunde.nl

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Nonvalvular Atrial fibrillation Patients with a Non-Sex-Related CHA2DS2-VASc Score of 1

Coleman CI, Turpie AGG, Bunz TJ et al., Eur Heart J Cardiovasc Pharmacother. 2018

31 juli 2018

Coleman CI, Turpie AGG, Bunz TJ et al., Eur Heart J Cardiovasc Pharmacother. 2018

Global Prospective Safety Analysis of Rivaroxaban

Kirchhof P, Radaideh G, Kim Y-H et al., J Am Coll Cardiol 2018;: 72: 2 DOI: 10.1016/j.jacc.2018.04.058

9 juli 2018

Kirchhof P, Radaideh G, Kim Y-H et al., J Am Coll Cardiol 2018; 72: 2 DOI: 10.1016/j.jacc.2018.04.058

Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation

Andersson NW, Svanström H, Lund M et al., Int J Cardiol. 2018

3 juli 2018

Andersson NW, Svanström H, Lund M et al., Int J Cardiol. 2018

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation

Martinez BK, Sood NA, Bunz TJ et al. J Am Heart Assoc. 2018

23 apr. 2018

Martinez BK, Sood NA, Bunz TJ et al. J Am Heart Assoc. 2018

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Shah S, Norby FL, Datta YH et al., Blood advances 2018

4 feb. 2018

Shah S, Norby FL, Datta YH et al., Blood advances 2018

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach

Li X, Keshishian A, Hamilton M et al., PLoS ONE 2018

30 jan. 2018

Li X, Keshishian A, Hamilton M et al., PLoS ONE 2018

Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation

Hohnloser SH, Basic E, Hohmann C et al., Thromb Haemost. 2018

22 jan. 2018

Hohnloser SH, Basic E, Hohmann C et al., Thromb Haemost. 2018

Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany

Collings S-L, Lefevre C, Johnson ME et al., PLoS ONE 2017

8 jan. 2018

Collings S-L, Lefevre C, Johnson ME et al., PLoS ONE 2017

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients 80+ Years-of-Age with Nonvalvular Atrial Fibrillation

Coleman CI, Weeda ER, Nguyen E et al., Eur Heart J Qual Care Clin Outcomes. 2017

7 dec. 2017

Coleman CI, Weeda ER, Nguyen E et al., Eur Heart J Qual Care Clin Outcomes. 2017

Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation

Yao X, Tangri N, Gersh BJ et al., J Am Coll Cardiol. 2017

4 dec. 2017

Yao X, Tangri N, Gersh BJ et al., J Am Coll Cardiol. 2017

Real-life NOAC data; zinloze publicaties om snel te vergeten…?

4 okt. 2017 - Prof. dr. Menno Huisman / prof. dr. Freek Verheugt
Prof. dr. Menno Huisman en prof. dr. Freek Verheugt bespreken de waarde van registry-data voor keuze voor een NOAC. Registries geven aanvullende data, maar het maken van onderlinge vergelijkingen is gevaarlijk; alleen op basis van direct vergelijkende studies kan een keuze worden gemaakt.

Antistollingsdag 2017 Prof. dr. Menno Huisman en prof. dr. Freek Verheugt bespreken de waarde van data uit registries voor de keuze voor een specifieke NOAC. Registries geven aanvullende data, maar alleen op basis van direct vergelijkende studies kan een keuze worden gemaakt.

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis

López-López JA, Sterne JAC, Thom HHZ, BMJ 2017

28 nov. 2017

López-López JA, Sterne JAC, Thom HHZ, BMJ 2017